AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie developed Product Rights, Net ($M) ($M)
Form 10-Q / 10-K Goodwill & Intangible Assets Note
Latest, FY2025
46,390
Period ended Dec 31, 2025
Change on a year earlier
-12.8%
53,175 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Developed Product Rights, Net ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46,390 | -12.8% | Form 10-Q (filed 2026-08-03) ↗ |
| FY2024 | Dec 31, 2024 | 53,175 | +0.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 52,687 | -16.0% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 62,695 | -11.0% | Form 10-K (filed 2024-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 70,482 | -7.4% | Form 10-K (filed 2023-02-17) ↗ |
| FY2020 | Dec 31, 2020 | 76,087 | +479.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 13,142 | +28.1% | Form 10-K (filed 2021-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 10,258 | -8.0% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 11,156 | -8.6% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 12,208 | +136.6% | Form 10-K (filed 2018-02-16) ↗ |
| FY2015 | Dec 31, 2015 | 5,159 | – | Form 10-K (filed 2017-02-17) ↗ |
Breakdown
What makes up developed product rights, net ($m)
Cite this data
StockData. (2026). AbbVie Developed Product Rights, Net ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/intang_dpr_net
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.